HTA166 Cost-Effectiveness of Combination Pertuzumab+Trastuzumab Vs Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer (HER2+ eBC) in the Czech Republic
作者
S Motylova,Jan Doležel,Jan Novák,M. Pour,K. Krihova,David A. Skalicky
出处
期刊:Value in Health [Elsevier BV] 日期:2023-12-01卷期号:26 (12): S351-S351